Skip to content

Study · Case report or series · n = 1 · 2024

1 result

Euglycemic Ketoacidosis From Semaglutide in a Patient Without Diabetes.

Sood N, Bansal O, Garg R, Hoskote A

JCEM case reports30 Aug 2024Cited by 12 (Europe PMC)

PMID39221223 (opens in a new tab)PMCIDPMC11362620 (opens in a new tab)DOI10.1210/jcemcr/luae156 (opens in a new tab)PepBankPUB-39221223
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Euglycemic ketoacidosis is a medical emergency characterized by euglycemia, metabolic acidosis, and ketonemia. It is a well-recognized adverse event in patients with diabetes taking sodium-glucose cotransporter-2 inhibitors. However, little has been reported about euglycemic ketoacidosis using glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide. We present a case of euglycemic ketoacidosis in a young female without diabetes who was taking semaglutide for weight loss for the last 7 months. She was treated with bicarbonate-containing dextrose infusion, which improved the ketoacidosis rapidly. The incidence of euglycemic ketoacidosis will likely increase with the increasing use of GLP-1 inhibitors, and recognizing the signs and symptoms of this life-threatening condition is essential to treat it effectively. Our literature search identified 1 reported case of euglycemic ketoacidosis in a patient without diabetes associated with tirzepatide but none with semaglutide.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In a young woman without diabetes who took semaglutide for weight loss for 7 months, euglycemic ketoacidosis developed.

    In plain wordsIn one young woman without diabetes who took semaglutide for weight loss, a serious acid build-up with normal blood sugar developed.

    Peptide
    Semaglutide
    Outcome
    Not applicableEuglycemic ketoacidosis in a patient without diabetes
    Study

    n = 1

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 7 monthsAs given in this study (human).

    Source sentences

    Summary
    We present a case of euglycemic ketoacidosis in a young female without diabetes who was taking semaglutide for weight loss for the last 7 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.